NYSE · Asset Management · USD

Abrdn Life Sciences Investors (HQL) Stock Analysis

Abrdn Life Sciences Investors (HQL) is a Asset Management stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

HQL

$17.92

+$0.13 (+0.73%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HQL with… →

HQL Key Statistics

As of Oct 21, 2026

Trading

Open: $17.82
Previous Close: $17.79
Day's Range: 17.81–18.06
52-Week Range: 15.66–22.67
Volume: 97.19K
Beta: 0.73

Valuation

P/E Ratio: 2.70
EPS (ttm): 6.64

Financials (FY)

Revenue (FY): $86.39M−0.35%
Net Income (FY): $85.59M+0.35%
Profit margin: 17,856.98%
1-Year Return: +17.16%

Dividend and dates

Dividend: $2.24+12.59%
Ex-Dividend Date: August 24, 2026
Avg Volume: 145.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HQL closed at $17.92, +17.16% over 1 year.

In fiscal 2025, HQL reported revenue of $86.39M.

HQL Stock Return by Calendar Year

Abrdn Life Sciences Investors (HQL) 10-year return: what $10,000 became

1 year: $10,000 $11,716; +17.16%
5 years: $10,000 $14,567; +45.67%
10 years: $10,000 $26,808; +168.08%

If you had invested $10,000 in Abrdn Life Sciences Investors (HQL) 10 years ago, at the close on October 21, 2016, it would have been worth $26,808 at the close on October 21, 2026: +168.08% in total, +10.36% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−19.21%+45.48%+13.95%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+13.95%
2025	+45.48%
2024	+11.03%
2023	+4.23%
2022	−19.21%
2021	+5.52%
2020	+23.72%
2019	+25.53%
2018	−16.18%
2017	+25.41%
2016 (partial year)	−9.73%

As of October 21, 2026.

HQL Revenue and Earnings by Fiscal Year

FY ends September

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$86.39M	$85.59M	99.1%
2024	$86.69M	$85.30M	98.4%
2023	$23.52M	$22.35M	95.0%
2022	−$103.25M	−$104.60M	101.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$86.39M	—	—	$85.59M	99.1%
2024	$86.69M	—	—	$85.30M	98.4%
2023	$23.52M	—	—	$22.35M	95.0%
2022	−$103.25M	—	—	−$104.60M	101.3%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

HQL Dividend History

’16’17’18’19’20’21’22’23’24’25’26*

$1.82−2.2% vs 2024

Dividends per share, 2025 · 4 payments

Year	Dividends per share	Payments	Change
2026*	$1.74	3	—
2025	$1.82	4	−2.2%
2024	$1.86	4	+46.5%
2023	$1.27	4	−6.6%

Year	Dividends per share	Payments	Change
2026 (partial year)	$1.74	3	—
2025	$1.82	4	−2.2%
2024	$1.86	4	+46.5%
2023	$1.27	4	−6.6%
2022	$1.36	4	−19.5%
2021	$1.69	4	+8.3%
2020	$1.56	5	+11.4%
2019	$1.40	4	−13.6%
2018	$1.62	4	+0.0%
2017	$1.62	4	+305.0%
2016	$0.40	1	—

Most recent payment: $0.58 per share, ex-dividend August 24, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

HQL Valuation vs Asset Management Median

Median of 512 stocks

Metric	HQL	Asset Management median	vs median
P/E	2.70	9.44	0.3x the median
Profit margin	17,856.98%	74.97%	17,782.0 pts above

Medians across 512 Asset Management stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The record here covers Abrdn Life Sciences Investors, ticker HQL. It is classified in the Asset Management industry, within the Financial Services sector.

The 52-week range on file runs from $15.66 to $22.67. HQL last closed at $17.92 on October 21, 2026. That is +$0.13 (+0.73%) against the previous close. The latest close sits 14.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $86.39M. That is −0.35% against the prior fiscal year, when revenue was $86.69M. The same year closed with net income of $85.59M. That is +0.35% against the prior fiscal year. Profit margin runs at 17,856.98%. That is 17,782 percentage points above the Asset Management median of 74.97%. Earnings per share on a trailing basis come to 6.64.

Across the 4 fiscal years on file, revenue moves from −$103.25M in 2022 to $86.39M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

HQL trades at a trailing price-to-earnings ratio of 2.7. That is 0.3 times the Asset Management median of 9.44. 512 Asset Management companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +17.16%. Across 10 years the annualized return works out at +10.36%. The reported beta is 0.73. Daily returns over the trailing 10 years annualize to a volatility of 22.52%.

Growth & Income

Shareholders receive a dividend, yielding 12.59% on the latest price. That is 3.7 percentage points above the Asset Management median yield of 8.91%. At the indicated rate that is $2.24 a share a year. The ex-dividend date on file is August 24, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $1.74 a share. The year before, 2025, totalled $1.82 a share.

2026 is still running; the total return is +13.95% year to date. Across the complete calendar years on file, 2025 returned +45.48% and 2022 returned −19.21%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Abrdn Life Sciences Investors (HQL) operates in the Asset Management industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Abrdn Life Sciences Investors	HQL	—	2.7
BlackRock, Inc.	BLK	$184.31B	25.8
Blackstone Inc.	BX	$127.43B	23.9
Brookfield Corporation	BN	$83.74B	69.5

The Asset Management industry average P/E ratio is 9.4x. Abrdn Life Sciences Investors trades at a P/E of 2.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Asset Management Stocks

BLK

BlackRock, Inc.

$184.31B

Blackstone Inc.

$127.43B

Brookfield Corporation

$83.74B

KKR

KKR & Co. Inc.

$83.00B

BAM

Brookfield Asset Management Ltd.

$73.36B

APO

Apollo Global Management, Inc.

$65.96B

View all Asset Management stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.11T

JPM

JPMorgan Chase & Co.

$890.13B

Visa Inc.

$765.68B

Mastercard Incorporated

$545.42B

BAC

Bank of America Corporation

$358.24B

View all Financial Services stocks →

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.